Revisiting ‘intensive’ blood glucose control: A causal directed acyclic graph‐guided systematic review of randomized controlled trials
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Revisiting ‘intensive’ blood glucose control: A causal directed acyclic graph‐guided systematic review of randomized controlled trials
Authors
Keywords
-
Journal
DIABETES OBESITY & METABOLISM
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2022-07-18
DOI
10.1111/dom.14819
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs
- (2022) Dario Giugliano et al. Cardiovascular Diabetology
- Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis
- (2021) Kazem Rahimi et al. LANCET
- The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
- (2021) Matthew J Page et al. BMJ-British Medical Journal
- Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis
- (2021) Kazem Rahimi et al. LANCET
- Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND
- (2021) Manige Konig et al. Cardiovascular Diabetology
- Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials
- (2021) Naveed Sattar et al. Lancet Diabetes & Endocrinology
- The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial
- (2020) Hertzel C Gerstein et al. Lancet Diabetes & Endocrinology
- Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial
- (2020) John B. Buse et al. DIABETES CARE
- Using the BRAVO Risk Engine to Predict Cardiovascular Outcomes in Clinical Trials With Sodium–Glucose Transporter 2 Inhibitors
- (2020) Hui Shao et al. DIABETES CARE
- Relationship between improvement of glycaemic control and reduction of major cardiovascular events in 15 cardiovascular outcome trials: A meta‐analysis with meta‐regression
- (2020) Dario Giugliano et al. DIABETES OBESITY & METABOLISM
- Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes
- (2020) Mark C. Petrie et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
- (2020) Milton Packer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dapagliflozin in Patients with Chronic Kidney Disease
- (2020) Hiddo J.L. Heerspink et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status
- (2020) Stefan D. Anker et al. CIRCULATION
- Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease
- (2020) Deepak L. Bhatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Co-Transporter 2 Inhibitors for Prevention of MajorAdverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials
- (2019) Thomas A. Zelniker et al. CIRCULATION
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Heterogeneity and Similarities in GLP-1 Receptor Agonist Cardiovascular Outcomes Trials
- (2019) Irene Caruso et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Neuroprotective Mechanisms of Glucagon-like Peptide-1-based Therapies in Ischaemic Stroke: A Systematic Review based on Pre-Clinical Studies
- (2018) Ida R. Marlet et al. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
- Blood glucose reduction by diabetic drugs with minimal hypoglycaemia risk for cardiovascular outcomes: Evidence from meta-regression analysis of randomized controlled trials
- (2018) Chi-Jung Huang et al. DIABETES OBESITY & METABOLISM
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2018) Thomas A Zelniker et al. LANCET
- The GRADE Working Group clarifies the construct of certainty of evidence
- (2017) Monica Hultcrantz et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Estimating data from figures with a Web-based program: Considerations for a systematic review
- (2017) Brittany U. Burda et al. Research Synthesis Methods
- Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis
- (2016) Sunder Mudaliar et al. DIABETES CARE
- Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor AlogliptinNovelty and Significance
- (2016) William B. White et al. HYPERTENSION
- Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes
- (2016) Suetonia C. Palmer et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Sodium–glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis
- (2016) Harindra Rajasekeran et al. KIDNEY INTERNATIONAL
- Hypoglycemia and risk of vascular events and mortality: a systematic review and meta-analysis
- (2015) Jong Shiuan Yeh et al. ACTA DIABETOLOGICA
- Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes
- (2015) R. Chilton et al. DIABETES OBESITY & METABOLISM
- Sirtuin 6 Expression and Inflammatory Activity in Diabetic Atherosclerotic Plaques: Effects of Incretin Treatment
- (2014) Maria Luisa Balestrieri et al. DIABETES
- Hypoglycemia and Risk of Cardiovascular Disease and All-Cause Mortality in Insulin-Treated People With Type 1 and Type 2 Diabetes: A Cohort Study
- (2014) Kamlesh Khunti et al. DIABETES CARE
- Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes
- (2014) Rury R Holman et al. LANCET
- Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials
- (2013) M. Monami et al. DIABETES OBESITY & METABOLISM
- Meta-analyses: heterogeneity and subgroup analysis
- (2013) P. Sedgwick BMJ-British Medical Journal
- Association of Clinical Symptomatic Hypoglycemia With Cardiovascular Events and Total Mortality in Type 2 Diabetes: A nationwide population-based study
- (2012) P.-F. Hsu et al. DIABETES CARE
- Glucagon-Like Peptide (GLP)-1(9-36)Amide-Mediated Cytoprotection Is Blocked by Exendin(9-39) Yet Does Not Require the Known GLP-1 Receptor
- (2010) Kiwon Ban et al. ENDOCRINOLOGY
- A basic introduction to fixed-effect and random-effects models for meta-analysis
- (2010) Michael Borenstein et al. Research Synthesis Methods
- Intensive glucose control and macrovascular outcomes in type 2 diabetes
- (2009) F. M. Turnbull et al. DIABETOLOGIA
- Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Intensive Glucose Lowering in Type 2 Diabetes
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
- 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
- (2008) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes
- (2008) William Duckworth et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation